Form 4: AngioDynamics Director Wesley Johnson Receives Annual Stock Compensation

Sentiment:

Insider Transaction Report


AngioDynamics Inc. Director Wesley Johnson was granted 17,675 restricted stock units as part of his annual compensation, which vested immediately.

Summary

  • Wesley Johnson, a Director of AngioDynamics Inc. (ANGO), acquired 17,675 shares of common stock.
  • The acquisition occurred on July 16, 2025, and represents restricted stock units (RSUs) granted as regular annual compensation for his service as a director.
  • The granted restricted stock units vested immediately upon grant.
  • Following this transaction, Wesley Johnson beneficially owns 143,538 shares of AngioDynamics common stock.
  • The transaction price for the acquired shares was $0, indicating a grant rather than a purchase.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates ongoing director commitment and aligns interests through equity compensation, which is a standard and expected practice.

Positives

  • Grant of 17,675 restricted stock units to a director, aligning management interests with shareholders.
  • The restricted stock units vested immediately, providing immediate ownership to the director.

Risks

  • The Power of Attorney document mentions that the authority granted remains in effect until the PoA Party is no longer required to file Forms 3, 4, and 5, implying ongoing regulatory compliance obligations.

Future Outlook

Not applicable, as this is a report of a past transaction and does not contain forward-looking statements or guidance.

Industry Context

This is a routine insider compensation filing, common across all industries for public companies. It reflects standard corporate governance practices regarding director compensation.

Comparison to Industry Standards

  • Director compensation often includes equity grants like Restricted Stock Units (RSUs) to align interests with shareholders, which is a standard practice in publicly traded companies, including those in the medical device industry like AngioDynamics.
  • The immediate vesting of the RSUs is a common feature for director compensation, ensuring immediate ownership and commitment.

Management Changes

RolePrevious PersonNew PersonEffective DateReason
Attorney-in-Fact for Wesley Johnson, Jr.Stephen A. TrowbridgeLawrence T. Weiss2025-01-20Substitution of attorney-in-fact for SEC filing purposes.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Administrative Change (Power of Attorney)Substitution of Lawrence T. Weiss as attorney-in-fact for Director Wesley Johnson, Jr. for the purpose of executing SEC Forms 3, 4, and 5.2025-01-20Ensures continuity and proper authorization for regulatory filings related to insider transactions.

Stakeholder Impact

  • Shareholders: The grant of RSUs to a director aligns the director's financial interests with those of shareholders, potentially encouraging decisions that enhance shareholder value. It also represents a form of dilution, though minor in this context.
  • Director (Wesley Johnson): Receives equity compensation for service, increasing personal stake in the company.

Next Steps

  • Ongoing compliance with Section 16 filing requirements for future transactions or changes in beneficial ownership.

Key Dates

DateDescription
2025-01-20Date of Substitute Power of Attorney appointing Lawrence T. Weiss as attorney-in-fact for Wesley Johnson, Jr.
2025-07-16Date of transaction: acquisition of 17,675 restricted stock units by Director Wesley Johnson.
2025-07-18Date of filing of the Form 4 statement.

Keywords

AngioDynamics, ANGO, Wesley Johnson, Director, Restricted Stock Units, RSU, Stock Compensation, Insider Transaction, Form 4, SEC Filing, Corporate Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.